Literature DB >> 27062154

Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.

Priscila H Goncalves1, Stephanie L Peterson2, Fawn D Vigneau1, Ronald D Shore1, William O Quarshie3, Khairul Islam4, Ann G Schwartz1, Antoinette J Wozniak1, Shirish M Gadgeel1.   

Abstract

BACKGROUND: Brain metastases (BM) remain an important cause of morbidity and mortality in patients with lung cancer. The current study evaluated population-based incidence and outcomes of BM in patients with nonmetastatic lung cancer.
METHODS: Patients diagnosed with nonmetastatic first primary lung cancer between 1973 and 2011 in the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) registry were used for the current analysis. Age-adjusted odds ratios of developing BM based on various demographic characteristics and histology were calculated with 95% confidence intervals. Adjusted Cox proportional hazard ratios and log-rank tests of Kaplan-Meier survival curves were calculated to evaluate survival differences for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
RESULTS: The incidence of BM in patients with nonmetastatic NSCLC and SCLC was 9% and 18%, respectively. There was variation in the incidence of BM according to NCSLC histology. The incidence of BM was higher in patients aged <60 years for both NSCLC and SCLC, but there were no differences noted by race for either histological group. Female patients with NSCLC were more likely to have BM than male patients. There was variation in the proportion of BM in both patients with NSCLC and SCLC over the three 13-year periods of diagnosis. The risk of death (hazard ratio) was found to be significantly higher for patients with NSCLC with BM, but was not significantly higher in patients with SCLC with BM.
CONCLUSIONS: The incidence of BM in patients with nonmetastatic lung cancer varies according to histology, age, and sex. BM are associated with worse survival for patients with NSCLC but not those with SCLC. Cancer 2016;122:1921-7.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  Surveillance, Epidemiology, and End Results (SEER); brain metastases; brain metastasis; lung cancer; nonmetastatic lung cancer

Mesh:

Year:  2016        PMID: 27062154      PMCID: PMC4892979          DOI: 10.1002/cncr.30000

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).

Authors:  Ryosuke Tsuchiya; Kenji Suzuki; Yukito Ichinose; Yoh Watanabe; Tsutomu Yasumitsu; Naoki Ishizuka; Harubumi Kato
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

2.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

3.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Authors:  R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

4.  Neoplasms of the central nervous system. Epidemiologic considerations.

Authors:  A K Percy; L R Elveback; H Okazaki; L T Kurland
Journal:  Neurology       Date:  1972-01       Impact factor: 9.910

5.  Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214.

Authors:  Elizabeth M Gore; Kyounghwa Bae; Stuart J Wong; Alexander Sun; James A Bonner; Steven E Schild; Laurie E Gaspar; Jeffery A Bogart; Maria Werner-Wasik; Hak Choy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

6.  Metastatic sites and survival in lung cancer.

Authors:  M Riihimäki; A Hemminki; M Fallah; H Thomsen; K Sundquist; J Sundquist; K Hemminki
Journal:  Lung Cancer       Date:  2014-08-02       Impact factor: 5.705

7.  Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age.

Authors:  A M Stark; C Stöhring; J Hedderich; J Held-Feindt; H M Mehdorn
Journal:  J Clin Neurosci       Date:  2010-09-20       Impact factor: 1.961

8.  Primary chemotherapy of brain metastasis in small-cell lung cancer.

Authors:  J S Lee; W K Murphy; B S Glisson; H M Dhingra; P Y Holoye; W K Hong
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

9.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

10.  Epidemiology of brain tumors: the national survey of intracranial neoplasms.

Authors:  A E Walker; M Robins; F D Weinfeld
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

View more
  39 in total

1.  Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.

Authors:  Grégory Kuchcinski; Emilie Le Rhun; Alexis B Cortot; Elodie Drumez; Romain Duhal; Maxime Lalisse; Julien Dumont; Renaud Lopes; Jean-Pierre Pruvo; Xavier Leclerc; Christine Delmaire
Journal:  Eur Radiol       Date:  2017-02-16       Impact factor: 5.315

Review 2.  Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.

Authors:  Johnathan D Ebben; Ming You
Journal:  Int J Biochem Cell Biol       Date:  2016-07-27       Impact factor: 5.085

3.  Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases.

Authors:  Kung-Chu Ho; Cheng-Hong Toh; Shih-Hong Li; Chien-Ying Liu; Cheng-Ta Yang; Yu-Jen Lu; Tzu-Pei Su; Chih-Wei Wang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-10       Impact factor: 9.236

4.  The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases.

Authors:  C Nieder; M Hintz; O Oehlke; A Bilger; A L Grosu
Journal:  Clin Transl Oncol       Date:  2017-03-29       Impact factor: 3.405

5.  Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study.

Authors:  Courtney Kromer; Jordan Xu; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Raymond Sawaya; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2017-05-31       Impact factor: 4.130

6.  Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease.

Authors:  Surein Arulananda; Hongdo Do; Gareth Rivalland; Zoe Loh; Ashan Musafer; Eddie Lau; Paul Mitchell; Alexander Dobrovic; Thomas John
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

7.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Authors:  Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

8.  Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases.

Authors:  Ling-Ling Kong; Lin-Lin Wang; Li-Gang Xing; Jin-Ming Yu
Journal:  Chronic Dis Transl Med       Date:  2017-12-12

9.  The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.

Authors:  Heng Shen; Gang Deng; Qianxue Chen; Jin Qian
Journal:  BMC Cancer       Date:  2021-07-16       Impact factor: 4.430

Review 10.  State-of-the-art considerations in small cell lung cancer brain metastases.

Authors:  Rimas V Lukas; Vinai Gondi; David O Kamson; Priya Kumthekar; Ravi Salgia
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.